{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T11:16:17Z","timestamp":1783682177089,"version":"3.55.0"},"reference-count":74,"publisher":"SAGE Publications","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Cephalalgia"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Migraine is a common condition that causes a high burden of disability even at a young age, significantly affecting various aspects of quality of life. Despite this significant burden, the pharmacological treatment of migraine is still a subject of debate, with controversial results that do not provide sufficient evidence of its effectiveness. Furthermore, the safety profile in this inherently fragile population leaves some doubts about pharmacological prophylaxis use. This study aims to provide an overview of the safety profile of the main drugs used in populations of children and adolescents with migraine, analysing the type and frequency of the main side effects reported.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>PubMed and Scopus were systematically searched for papers reporting adverse events (AEs) of pharmacological prophylaxis of migraine in children and adolescents, and all eligible original articles were included. A meta-analysis was carried out to define the pooled proportion of the summary safety information (i.e. the number of subjects reporting at least one AE) with 95% confidence intervals for those compounds present in at least two samples, regardless of dosage.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In total, 40 studies were included, accounting for 62 subsamples and 2742 patients (55% females). The most used compounds were topiramate (22 subsamples), propranolol and sodium valproate (six subsamples). Overall, 30% of patients reported at least one AE. Erenumab showed the highest rate of AEs, most likely due to the higher-precision detection typical of a randomized controlled trial, and cinnarizine the lowest. In total, 53 different AEs were reported, most frequently drowsiness, anorexia, fatigue and paraesthesia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In accordance with the results of this systematic review with a meta-analysis, clinicians should consider that 30% of the paediatric patients with migraine will report some AEs from prevention treatment. The information on the safety profile is essential for clinicians in evaluating the choice of a specific therapy, making a better risk\/benefit ratio evaluation for each single patient, which is crucial in consideration of the inconsistent efficacy profiles of preventive medications, with the exception of topiramate, in this population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/03331024261441586","type":"journal-article","created":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T14:20:29Z","timestamp":1783434029000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Iatrogenic harm in paediatric and adolescent populations of patients with migraine: A systematic review with meta-analysis"],"prefix":"10.1177","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4834-2045","authenticated-orcid":false,"given":"Danilo Antonio","family":"Montisano","sequence":"first","affiliation":[{"name":"Headache Center, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gandini","family":"Giulia","sequence":"additional","affiliation":[{"name":"Headache Center, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcassoli","family":"Alessia","sequence":"additional","affiliation":[{"name":"Fondazione IRCCS Istituto Neurologico Carlo Besta"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corso","family":"Barbara","sequence":"additional","affiliation":[{"name":"National Research Council"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6535-1109","authenticated-orcid":false,"given":"Grazzi","family":"Licia","sequence":"additional","affiliation":[{"name":"Headache Center, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7433-7779","authenticated-orcid":false,"given":"Raggi","family":"Alberto","sequence":"additional","affiliation":[{"name":"Fondazione IRCCS Istituto Neurologico Carlo Besta"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parisi","family":"Alessandra","sequence":"additional","affiliation":[{"name":"Headache Center, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,7,7]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-024-01889-x"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-025-02145-6"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1177\/03331024251331217"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-023-01541-0"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-8749.2010.03793.x"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(25)00402-8"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph18010250"},{"key":"e_1_3_3_9_2","first-page":"09","article-title":"Experts\u2019 opinion about the primary headache diagnostic criteria of the ICHD-3rd edition beta in children and adolescents","volume":"18","author":"\u00d6zge A","year":"2017","unstructured":"\u00d6zge A, Faedda N, Abu-Arafeh I, et al. Experts\u2019 opinion about the primary headache diagnostic criteria of the ICHD-3rd edition beta in children and adolescents. J Headache Pain 2017; 18: 09.","journal-title":"J Headache Pain"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-017-2865-1"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.5124\/jkma.2017.60.2.118"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-018-1073-9"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2019.00793"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-021-01262-2"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamapediatrics.2019.5856"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.38666"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamapediatrics.2013.508"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1610384"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2018.0046"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000008105"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-025-02527-z"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.327.7414.557"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/head.13754"},{"key":"e_1_3_3_25_2","article-title":"Flunarizine versus propranolol in prophylaxis of pediatric migraine: an open-label randomized trial","volume":"16","author":"Vaswani ND","year":"2024","unstructured":"Vaswani ND, Lamba P, Arya V, et al. Flunarizine versus propranolol in prophylaxis of pediatric migraine: an open-label randomized trial. Cureus 2024; 16: e74563.","journal-title":"Cureus"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13760-012-0011-7"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.2331"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-8749.2011.04154.x"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12051802"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1177\/08830738221092882"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12098-022-04279-w"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pmn.2023.04.006"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.18071\/isz.77.0122"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13755"},{"key":"e_1_3_3_35_2","first-page":"32","article-title":"Evaluation efficacy of ferrous sulfate therapy on headaches of 5-15 years old iron deficient children with migraine","volume":"6","author":"Fallah R","year":"2016","unstructured":"Fallah R, Zare Bidoki S, Ordooei M. Evaluation efficacy of ferrous sulfate therapy on headaches of 5-15 years old iron deficient children with migraine. Iran J Ped Hematol Oncol 2016; 6: 32\u201337.","journal-title":"Iran J Ped Hematol Oncol"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1177\/03331024211007789"},{"key":"e_1_3_3_37_2","first-page":"276","article-title":"Comparison of propranolol and pregabalin for prophylaxis of childhood migraine: a randomised controlled trial","volume":"53","author":"Bali M B","year":"2015","unstructured":"Bali M B, Rahbarimanesh AA, Sadeghi M, et al. Comparison of propranolol and pregabalin for prophylaxis of childhood migraine: a randomised controlled trial. Acta Med Iran 2015; 53: 276\u2013280.","journal-title":"Acta Med Iran"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pediatrneurol.2014.05.031"},{"key":"e_1_3_3_39_2","article-title":"Further evidence that onabotulinum toxin is a viable treatment option for pediatric chronic migraine patients","volume":"11","author":"Ali SS","year":"2019","unstructured":"Ali SS, Bragin I, Rende E, et al. Further evidence that onabotulinum toxin is a viable treatment option for pediatric chronic migraine patients. Cureus 2019; 11: e4343.","journal-title":"Cureus"},{"key":"e_1_3_3_40_2","first-page":"121","article-title":"Comparing pregabalin and sodium valproate in pediatric migraine prophylaxis: a randomized clinical trial","volume":"17","author":"Jafari N","year":"2023","unstructured":"Jafari N, Nasehi MM, Nasiri Eghbali A, et al. Comparing pregabalin and sodium valproate in pediatric migraine prophylaxis: a randomized clinical trial. Iran J Child Neurol 2023; 17: 121\u2013131.","journal-title":"Iran J Child Neurol"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.2165\/11316270-000000000-00000"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.5114\/polp.2019.86434"},{"key":"e_1_3_3_43_2","first-page":"180","article-title":"Sodium valproate versus topiramate for prophylaxis of migraine among children and adolescents: a randomised trial","volume":"18","author":"Yadav R ST","year":"2017","unstructured":"Yadav R ST, Shukla SK. Sodium valproate versus topiramate for prophylaxis of migraine among children and adolescents: a randomised trial. J Indian Acad Clin Med 2017; 18: 180\u2013183.","journal-title":"J Indian Acad Clin Med"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2005.00262.x"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2006.00610.x"},{"key":"e_1_3_3_46_2","doi-asserted-by":"publisher","DOI":"10.1177\/0883073808318547"},{"key":"e_1_3_3_47_2","first-page":"480","article-title":"Topiramate for migraine prophylaxis among children aged 5 to 15 years","volume":"33","author":"Surani MK","year":"2021","unstructured":"Surani MK, Yousuf M, Anjum N, et al. Topiramate for migraine prophylaxis among children aged 5 to 15 years. J Ayub Med Coll Abbottabad 2021; 33: 480\u2013483.","journal-title":"J Ayub Med Coll Abbottabad"},{"key":"e_1_3_3_48_2","first-page":"71","article-title":"Topiramate for migraine prophylaxis in children","volume":"30","author":"Saleem SF QI","year":"2019","unstructured":"Saleem SF QI, Rehman A. Topiramate for migraine prophylaxis in children. Medical Forum Monthly 2019; 30: 71\u201374.","journal-title":"Medical Forum Monthly"},{"key":"e_1_3_3_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pediatrneurol.2021.12.008"},{"key":"e_1_3_3_50_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2008-0642"},{"key":"e_1_3_3_51_2","doi-asserted-by":"publisher","DOI":"10.1177\/0883073807304201"},{"key":"e_1_3_3_52_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpn.2012.10.001"},{"key":"e_1_3_3_53_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12098-013-0976-0"},{"key":"e_1_3_3_54_2","first-page":"7","article-title":"The efficacy and safety of topiramate for prophylaxis of migraine in children","volume":"7","author":"Fallah R","year":"2013","unstructured":"Fallah R, Akhavan Karbasi S, Shajari A, et al. The efficacy and safety of topiramate for prophylaxis of migraine in children. Iran J Child Neurol 2013; 7: 7\u201311.","journal-title":"Iran J Child Neurol"},{"key":"e_1_3_3_55_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pediatrneurol.2009.04.020"},{"key":"e_1_3_3_56_2","first-page":"251","article-title":"Topiramate in the prophylactic treatment of migraine in children","volume":"20","author":"Campistol J","year":"2005","unstructured":"Campistol J, Campos J, Casas C, et al. Topiramate in the prophylactic treatment of migraine in children. J Child Neurol 2005; 20: 251\u2013253.","journal-title":"J Child Neurol"},{"key":"e_1_3_3_57_2","first-page":"18","article-title":"Cinnarizine versus topiramate in prophylaxis of migraines among children and adolescents: a randomized, double-blind clinical trial","volume":"8","author":"Ashrafi MR","year":"2014","unstructured":"Ashrafi MR, Najafi Z, Shafiei M, et al. Cinnarizine versus topiramate in prophylaxis of migraines among children and adolescents: a randomized, double-blind clinical trial. Iran J Child Neurol 2014; 8: 18\u201327.","journal-title":"Iran J Child Neurol"},{"key":"e_1_3_3_58_2","doi-asserted-by":"publisher","DOI":"10.1177\/0333102419888485"},{"key":"e_1_3_3_59_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2007.00867.x"},{"key":"e_1_3_3_60_2","first-page":"77","article-title":"Efficacy of topiramate alone and topiramate plus vitamin D3 in the prophylaxis of pediatric migraine: a randomized clinical trial","volume":"14","author":"Fallah R","year":"2020","unstructured":"Fallah R, Sarraf Yazd S, Sohrevardi SM. Efficacy of topiramate alone and topiramate plus vitamin D3 in the prophylaxis of pediatric migraine: a randomized clinical trial. Iran J Child Neurol 2020; 14: 77\u201386.","journal-title":"Iran J Child Neurol"},{"key":"e_1_3_3_61_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pediatrneurol.2005.06.001"},{"key":"e_1_3_3_62_2","doi-asserted-by":"publisher","DOI":"10.4103\/1817-1745.106470"},{"key":"e_1_3_3_63_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-022-02346-4"},{"key":"e_1_3_3_64_2","doi-asserted-by":"publisher","DOI":"10.1177\/0333102419888222"},{"key":"e_1_3_3_65_2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1407897"},{"key":"e_1_3_3_66_2","unstructured":"Administration FaD. Amitriptyline Hydrochloride Tablets USP: Prescribing Information \u2013 Clinical Worsening and Suicide Risk 2025. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/085968s112lbl.pdf (accessed 22 December 2025)."},{"key":"e_1_3_3_67_2","unstructured":"Administration FaD. Topamax (topiramate) sprinkle capsules and oral tablets: Prescribing Information 2012. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/020844s041lbl.pdf?utm_source=chatgpt.com (accessed 22 December 2025)."},{"key":"e_1_3_3_68_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2012.505"},{"key":"e_1_3_3_69_2","doi-asserted-by":"publisher","DOI":"10.1097\/j.pain.0000000000001456"},{"key":"e_1_3_3_70_2","doi-asserted-by":"publisher","DOI":"10.1111\/ene.13621"},{"key":"e_1_3_3_71_2","unstructured":"Administration FaD. Depacon (valproate sodium) injection: Prescribing Information 2013. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/020593s026lbl.pdf?utm_source=chatgpt.com (accessed 22 December 2025)."},{"key":"e_1_3_3_72_2","unstructured":"Administration FaD. Propranolol: Prescribing Information 2011. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/016418s080 016762s017 017683s008lbl.pdf (accessed 22 December 2025)."},{"key":"e_1_3_3_73_2","doi-asserted-by":"publisher","DOI":"10.1177\/03331024251374686"},{"key":"e_1_3_3_74_2","doi-asserted-by":"publisher","DOI":"10.1111\/head.13459"},{"key":"e_1_3_3_75_2","doi-asserted-by":"publisher","DOI":"10.4081\/cc.2025.15782"}],"container-title":["Cephalalgia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03331024261441586","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/03331024261441586","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03331024261441586","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T10:47:30Z","timestamp":1783680450000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/03331024261441586"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":74,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1177\/03331024261441586"],"URL":"https:\/\/doi.org\/10.1177\/03331024261441586","relation":{},"ISSN":["0333-1024","1468-2982"],"issn-type":[{"value":"0333-1024","type":"print"},{"value":"1468-2982","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]},"article-number":"03331024261441586"}}